Loading data
PCVXNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development expense | 794.31 m USD | 476.64 m USD | 332.34 m USD | 169.45 m USD | 78.41 m USD |
| Operating profit | -923.68 m USD | -569.55 m USD | -468.04 m USD | -232.26 m USD | -103.67 m USD |
| Interest expense | — | — | 0 USD | 2 k USD | 7 k USD |
| Income tax expense | 0 USD | 0 USD | 0 USD | — | — |
| Net income (reported basis) | -766.63 k USD | -463.93 k USD | -402.27 k USD | -223.49 k USD | -100.08 k USD |
| Net income attributable to common shareholders | -766.63 m USD | -463.93 m USD | -402.27 m USD | -223.49 m USD | -100.08 m USD |
| Basic earnings per share | -5.63 USD/share | -3.8 USD/share | -4.14 USD/share | -3.44 USD/share | -1.93 USD/share |
| Diluted earnings per share | -5.63 USD/share | -3.8 USD/share | -4.14 USD/share | -3.44 USD/share | -1.93 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.